Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 4/20 | 0.43 |
| ▸ | GLS | O94925 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 8/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25848861 | 0.92 | NAMPT (0.41) | BACE1NAMPTGLSELANERORC | |
| SCHEMBL25848940 | 0.83 | LSS (0.50) | RORCPPARD | |
| SCHEMBL25848970 | 0.80 | EPHX2 (0.44) | ELANE | |
| SCHEMBL25848961 | 0.79 | TRPV1 (0.48) | ELANEPPARD | |
| SCHEMBL25848972 | 0.79 | NAMPT (0.47) | NAMPTGLSRORC | |
| SCHEMBL25304798 | 0.76 | NAMPT (0.41) | NAMPTELANE | |
| SCHEMBL25848851 | 0.76 | EPHX2 (0.42) | NAMPT | |
| SCHEMBL25848823 | 0.75 | EPHX2 (0.61) | — | |
| SCHEMBL14562254 | 0.75 | KMT2A (0.49) | BACE1GLSSORT1 | |
| SCHEMBL31041221 | 0.75 | KMT2A (0.49) | BACE1GLSSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4175624-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| CN-116075297-A | KCNT1 inhibitors and methods of use | 普拉西斯精密医药公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2022010880-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | BACE1 664/4885NAMPT 378/4885GLS 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.